KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects.
about
Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria.MalariaDevelopment of medicines for the control and elimination of malaria
P2860
KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
KAE609 (Cipargamin), a New Spi ...... E609 in Healthy Male Subjects.
@en
KAE609 (Cipargamin), a New Spi ...... E609 in Healthy Male Subjects.
@nl
type
label
KAE609 (Cipargamin), a New Spi ...... E609 in Healthy Male Subjects.
@en
KAE609 (Cipargamin), a New Spi ...... E609 in Healthy Male Subjects.
@nl
prefLabel
KAE609 (Cipargamin), a New Spi ...... E609 in Healthy Male Subjects.
@en
KAE609 (Cipargamin), a New Spi ...... E609 in Healthy Male Subjects.
@nl
P2093
P2860
P356
P1476
KAE609 (Cipargamin), a New Spi ...... E609 in Healthy Male Subjects.
@en
P2093
Alexandre Luneau
Andreas Fredenhagen
Chun-qi Zhu
Daniel S Stein
Gangadhar Sunkara
James B Mangold
Jay P Jain
Jürgen Kühnöl
Su-Er W Huskey
P2860
P304
P356
10.1124/DMD.115.069187
P577
2016-02-26T00:00:00Z